Automate Your Wheel Strategy on MRK
With Tiblio's Option Bot, you can configure your own wheel strategy including MRK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MRK
- Rev/Share 25.4145
- Book/Share 19.5994
- PB 4.3321
- Debt/Equity 0.7226
- CurrentRatio 1.4236
- ROIC 0.1828
- MktCap 211787038461.0
- FreeCF/Share 5.8814
- PFCF 14.3858
- PE 12.9368
- Debt/Assets 0.3012
- DivYield 0.0382
- ROE 0.3488
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 3
- DCF Score 5
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | MRK | Citigroup | -- | Neutral | -- | $95 | Oct. 13, 2025 |
| Downgrade | MRK | Berenberg | Buy | Hold | -- | $90 | Sept. 17, 2025 |
| Downgrade | MRK | Citigroup | Buy | Neutral | -- | $84 | May 14, 2025 |
| Initiation | MRK | Cantor Fitzgerald | -- | Neutral | -- | $85 | April 22, 2025 |
| Downgrade | MRK | Deutsche Bank | Buy | Hold | $128 | $105 | Feb. 18, 2025 |
| Downgrade | MRK | TD Cowen | Buy | Hold | $121 | $100 | Feb. 10, 2025 |
| Downgrade | MRK | Truist | Buy | Hold | -- | $110 | Jan. 8, 2025 |
| Downgrade | MRK | BMO Capital Markets | Outperform | Market Perform | $136 | $105 | Dec. 20, 2024 |
| Resumed | MRK | BofA Securities | -- | Buy | -- | $121 | Dec. 10, 2024 |
| Upgrade | MRK | HSBC Securities | Hold | Buy | -- | $130 | Dec. 4, 2024 |
News
Flare Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate FX-909 in Combination with KEYTRUDA® (pembrolizumab) in New Cohort of Ongoing Phase 1 Trial in Metastatic Urothelial Cancer
Published: October 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for oncology and other therapeutic areas, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada). FX-909, a first-in-class orally available small molecule inhibitor of PPARG, the master regulator of the luminal lineage, will be evaluated in combination with KEYTRUDA ® (pembrolizumab), Merck's anti-PD-1 (programmed cell death receptor-1) therapy, in a new cohort within the company's ongoing Phase 1 study in …
Read More
Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) in U.S. Adults
Published: October 21, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Systematic Review of 15 Studies Focused on Epidemiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CAPVAXIVE in U.S. Adults.
Read More
My Top 3 Pharma Stocks
Published: October 20, 2025 by: Seeking Alpha
Sentiment: Positive
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Read More
Goldman Sachs Reveals Sectors With Top 2026 Payouts: 5 Strong Buys
Published: October 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Founded in 1869, Goldman Sachs is the world's second-largest investment bank by revenue and is ranked 55th on the Fortune 500 list of the largest United States corporations by total revenue.
Read More
2 Beaten-Down Stocks to Buy and Hold for the Next Decade
Published: October 20, 2025 by: The Motley Fool
Sentiment: Positive
The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means, among other things, buying shares of companies that are lagging the market but can bounce back over the midterm and beyond.
Read More
Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings?
Published: October 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Merck faces a sharp Gardasil slowdown as weak demand in China and Japan affects sales of the vaccine.
Read More
Is Trending Stock Merck & Co., Inc. (MRK) a Buy Now?
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Merck's New HIV Treatment Works As Well As Top Drug In Late Trials
Published: October 15, 2025 by: Benzinga
Sentiment: Positive
The relentless pursuit of innovative treatments in the pharmaceutical industry continues to reshape the landscape of chronic disease management. Merck & Co. Inc. (NYSE:MRK) on Wednesday announced additional data from two Phase 3 studies of a two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1 infection.
Read More
Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Here's Why Merck (MRK) is a Strong Momentum Stock
Published: October 13, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings?
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
MRK's Keytruda remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
Read More
High Margins, Lower Price: Is This Merck Stock's Buying Window?
Published: October 10, 2025 by: Forbes
Sentiment: Positive
Merck (MRK) stock merits your attention. Why? Because it offers monopoly-like high margins at a discounted price.
Read More
Jamie Dimon Issues Harsh Stock Market Warning – 5 of JPMorgan's Safest Dividend Stocks
Published: October 09, 2025 by: 24/7 Wall Street
Sentiment: Neutral
Jamie Dimon is one of the highest-profile bankers in the world. Like Warren Buffett, David Solomon, or other Wall Street titans, when he speaks, people listen.
Read More
MERCK INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Merck & Co., Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: October 08, 2025 by: GlobeNewsWire
Sentiment: Neutral
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Merck (MRK) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Merck between February 3, 2022, to February 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Read More
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck broadens its tulisokibart clinical program with three new phase IIb studies, deepening its reach across immune-mediated inflammatory diseases.
Read More
Merck Rises 13% in a Week: Should You Buy, Sell or Hold the Stock?
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Negative
MRK's stock witnesses an upside after Pfizer's pricing deal, but Gardasil's slump and Keytruda's looming LOE keep investors cautious.
Read More
How to trade the health care break out
Published: October 06, 2025 by: CNBC Television
Sentiment: Positive
The health care sector up 6.5% in one week. The Investment Committee debate how to trade the space.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Merck: A Race Against The Keytruda Clock
Published: October 03, 2025 by: Seeking Alpha
Sentiment: Positive
Merck (MRK) is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late-stage pipeline and R&D investments offer long-term growth potential. Recent political developments reduce regulatory risks, and the company's diversified operations and pipeline help buffer near-term uncertainties.
Read More
MRK Stock Up Nearly 14% So Far This Week: What's Driving It?
Published: October 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.
Read More
Top 10 High-Yield Dividend Stocks For October 2025
Published: October 01, 2025 by: Seeking Alpha
Sentiment: Positive
The October 2025 high-yield dividend watchlist highlights 10 stocks with an average forward yield of 3.95% and a projected 19.02% return. This month's selection process lowered the yield threshold to 2.5%, expanding the pool to 69 companies and increasing diversification opportunities. The watchlist has delivered a 15.01% CAGR since inception, outperforming its 12% target and offering higher starting yields than SPY and VYM.
Read More
3 Pharma Stocks Getting an Intraday Trump Bump
Published: September 30, 2025 by: Schaeffers Research
Sentiment: Positive
Pharmaceutical stocks are enjoying tailwinds today, after President Donald Trump announced the launch of a direct-to-consumer website dubbed "TrumpRX.
Read More
7 Ideal "Safer" Dividend Buys From 61 September Graham Value All-Stars (GVAS)
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
The article analyzes Large Cap Value (GASV) stocks using YCharts' Value Score and the Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Seven of fourteen 'safer' lowest-priced GASV Dogs—ET, MPLX, YRD, VZ, BMY, BBVA, and MFC—are highlighted as buyable for September 2025. Top ten GASV stocks are projected by analysts to deliver average net gains of 26.84% by September 2026, with Energy Transfer (ET) leading at 35.43%.
Read More
Merck: Initiating "Strong Buy" On Shift To Qlex SC Injection For Solid Tumors
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Positive
Merck earns a "Strong Buy" rating due to strategic moves, including FDA approval of QLEX, the first subcutaneous immune checkpoint inhibitor. QLEX extends Keytruda's patent life, offering rapid, flexible dosing and broader treatment settings, countering the upcoming IV Keytruda patent cliff in 2028. MRK's acquisition of Verona Pharma adds Ohtuvayre for COPD, expanding its cardiopulmonary portfolio and future growth opportunities.
Read More
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of Clinical Worsening Events by 76% Compared to Placebo in Patients Recently Diagnosed With PAH on Background Therapy in Phase 3 HYPERION Trial
Published: September 30, 2025 by: Business Wire
Sentiment: Neutral
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive results from the Phase 3 HYPERION trial evaluating WINREVAIR™ (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently diagnosed adults with pulmonary arterial hypertension (PAH, WHO* Group 1) functional class (FC) II or III at intermediate or high risk of disease progression. In the study, WINREVAIR reduced the risk of clinical worseni.
Read More
Big Pharma braces for the next price cut
Published: September 26, 2025 by: Proactive Investors
Sentiment: Negative
Drugmakers know the script by now. Washington picks a handful of blockbuster medicines, haggles with their makers, and then publishes the “maximum fair price” that Medicare will pay.
Read More
Merck: Game-Changing Oncology Drugs Power Stock Surge
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Positive
Despite the challenges Merck's vaccine franchise has faced, demand for its anti-cancer medications remains as high as ever. Welireg sales reached $162 million in Q2 2025, an increase of 18.2% quarter-on-quarter, thanks in part to its label expansion on May 14. Strong performance from two cardiovascular 'stars,' Winrevair and Adempas, led Merck to buy back about $1.35 billion in shares in Q2 2025, more than quadrupling year-on-year.
Read More
MRK vs. BMY: Which Pharma Stock Is the Smarter Pick Now?
Published: September 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Merck and Bristol Myers face diverging growth paths, with Keytruda driving MRK's momentum and BMY navigating generic headwinds.
Read More
Goldman Sachs Sees 4 Rate Cuts by Next Summer: 5 High-Yield Dividend Winners
Published: September 26, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks because they offer a significant income stream and have massive total return potential.
Read More
Merck: 25% Total Return CAGR Potential
Published: September 25, 2025 by: Seeking Alpha
Sentiment: Positive
Merck & Co. is rated a Strong Buy at $79.89, offering robust growth, a 4% yield, and significant undervaluation. MRK's pipeline, led by Keytruda derivatives and new blockbusters from acquisitions like Verona Pharma, is expected to offset patent expirations and drive future revenue. Dividend growth is projected at 6.5% CAGR, supported by a strong balance sheet, high profitability, and superior free cash flow versus peers.
Read More
About Merck & Co., Inc. (MRK)
- IPO Date 1978-01-13
- Website https://www.merck.com
- Industry Drug Manufacturers - General
- CEO Robert M. Davis
- Employees 73000